Health care pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 health care pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8). Figures as of 20 Nov 2026, 05:22 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 39.3
- Combined market value
- SAR 18.61T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | SAR 16.9B | SAR 154.43 | 0.48% down | 86% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | SAR 74.3B | SAR 554.47 | 1.06% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 9.8 | SAR 642.6B | SAR 145.80 | 1.42% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 9.9 | SAR 20.9B | SAR 30.76 | 3.19% down | 0% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.2 | SAR 447.3B | SAR 218.83 | 2.05% down | 30% up | ||
| 6 | ZoetisZTS · Health Care | 13.7 | SAR 123.1B | SAR 303.04 | 5.59% down | 26% down | ||
| 7 | GSKGSK · Health Care | 16.7 | SAR 359.5B | SAR 179.37 | 1.56% down | 5% up | ||
| 8 | Ascendis PharmaASND · Health Care | 16.8 | SAR 63B | SAR 960.11 | 5.32% down | 29% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 20.4 | SAR 358.3B | SAR 3,463.45 | 2.35% down | 28% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.1 | SAR 89.3B | SAR 2,097.18 | 3.16% down | 22% up | ||
| 11 | SanofiSNY · Health Care | 22.9 | SAR 414.9B | SAR 172.77 | 2.25% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 24.8 | SAR 1.02T | SAR 657.96 | 1.87% down | 1% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | SAR 30.4B | SAR 465.20 | 2.47% down | 51% up | ||
| 14 | NovartisNVS · Health Care | 29.6 | SAR 1.07T | SAR 567.23 | 2.57% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 33.5 | SAR 495.2B | SAR 1,953.00 | 2.94% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 39.0 | SAR 674.8B | SAR 389.62 | 0.58% down | 16% down | ||
| 17 | PfizerPFE · Health Care | 39.3 | SAR 588.8B | SAR 103.30 | 1.85% down | 15% up | ||
| 18 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.2 | SAR 46.4B | SAR 55.63 | 1.00% down | 8% up | ||
| 19 | Johnson & JohnsonJNJ · Health Care | 41.4 | SAR 2.41T | SAR 1,002.04 | 2.04% down | 34% up | ||
| 20 | GenmabGMAB · Health Care | 43.9 | SAR 118.8B | SAR 192.61 | 0.75% up | 70% up | ||
| 21 | Royalty PharmaRPRX · Health Care | 44.3 | SAR 146.1B | SAR 254.02 | 1.38% down | 79% up | ||
| 22 | Eli LillyLLY · Health Care | 44.9 | SAR 4.51T | SAR 5,068.05 | 2.29% down | 33% up | ||
| 23 | AbbVieABBV · Health Care | 48.7 | SAR 1.88T | SAR 1,063.56 | 0.86% down | 25% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 51.2 | SAR 26.7B | SAR 243.74 | 4.15% down | 10% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.8 | SAR 171.3B | SAR 1,499.27 | 0.97% down | 16% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 54.8 | SAR 28B | SAR 80.23 | 2.24% down | 90% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 70.0 | SAR 56.9B | SAR 886.92 | 4.57% down | 41% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | SAR 27.6B | SAR 350.85 | 1.59% down | 129% up | ||
| 29 | Teva Pharmaceutical IndustriesTEVA · Health Care | 89.6 | SAR 168.7B | SAR 144.56 | 8.74% down | 74% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | 98.3 | SAR 36.8B | SAR 243.36 | 1.88% down | 117% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 115 | SAR 21.5B | SAR 1,076.31 | 3.94% down | 50% up | ||
| 32 | Merck & CoMRK · Health Care | 134 | SAR 1.23T | SAR 498.17 | 3.61% down | 45% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 306 | SAR 256.6B | SAR 80.31 | 0.66% up | 51% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8) have the lowest P/E ratio of the 33 health care pharmaceutical companies ranked here as of 20 Nov 2026, 05:22 UTC.
How many health care pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 33 health care pharmaceutical companies ranked by P/E ratio have a combined market value of SAR 18.61T as of 20 Nov 2026, 05:22 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/E ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.